US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nuo Therapeutics, Inc.

1.67

+0.05003.09%

Volume:11.30K

Turnover:18.24K

Market Cap:80.29M

PE:-32.36

High:1.67

Open:1.54

Low:1.54

Close:1.62

52wk High:3.23

52wk Low:1.00

Shares:48.08M

Float Shares:22.86M

Volume Ratio:2.25

T/O Rate:0.05%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0516

EPS(LYR):-0.0293

ROE:-1032.50%

ROA:-87.97%

PB:-191.35

PE(LYR):-57.09

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Nuo Therapeutics Secures $1.6 Million Loan from Group of Lenders

Nuo Therapeutics Inc. Held Annual Shareholder Meeting

Nuo Therapeutics Initiated at Buy by Roth Capital

Nuo Therapeutics CEO/CFO David Emerson Reports Disposal of Common Shares

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AURX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AURX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AURX\",,,,,undefined,":{"symbol":"AURX","market":"US","secType":"STK","nameCN":"Nuo Therapeutics, Inc.","latestPrice":1.67,"timestamp":1770411600000,"preClose":1.62,"halted":0,"volume":11300,"delay":15,"changeRate":0.030864197530864085,"floatShares":22864200,"shares":48077700,"eps":-0.051611,"marketStatus":"Market Closed","change":0.05,"latestTime":"02-06 16:00:00 EST Delay","open":1.54,"high":1.67,"low":1.54,"amount":18244.64,"amplitude":0.080247,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.051611,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":1.62,"volumeRatio":2.2541392649607728},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AURX\",,,,,undefined,":{"symbol":"AURX","floatShares":22864200,"roa":"-87.97%","roe":"-1032.50%","lyrEps":-0.029253,"volumeRatio":2.2541392649607728,"shares":48077700,"dividePrice":0,"high":1.67,"amplitude":0.080247,"preClose":1.62,"low":1.54,"week52Low":1,"pbRate":"-191.35","psRate":"30.74","week52High":3.23,"institutionHeld":0,"latestPrice":1.67,"eps":-0.051611,"divideRate":0,"volume":11300,"delay":15,"ttmEps":-0.051611,"open":1.54,"prevYearClose":1.97,"prevWeekClose":1.7311,"prevMonthClose":1.7311,"prevQuarterClose":1.97,"fiveDayClose":1.7311,"twentyDayClose":1.973,"sixtyDayClose":2.55},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AURX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-12","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-19","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713499200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-20","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1700456400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AURX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AURX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1765861200000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AURX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2606226722","title":"Nuo Therapeutics Secures $1.6 Million Loan from Group of Lenders","url":"https://stock-news.laohu8.com/highlight/detail?id=2606226722","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606226722?lang=en_us&edition=fundamental","pubTime":"2026-01-27 05:26","pubTimestamp":1769462804,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics Inc. has entered into a new Loan and Security Agreement with four lenders, providing for loans totaling up to $1.6 million. The agreement includes an initial funding of $1.0 million, which closed on January 23, 2026, and a potential second funding of $600,000 available on September 30, 2026, subject to certain conditions. The loans are secured by a lien on all of the company's assets, including its intellectual property. Nuo Therapeutics plans to use the proceeds for general working capital purposes. As part of the deal, the company also issued warrants to the lenders to purchase shares of its common stock, with additional warrants to be issued as payment for accrued interest. Notably, two of the lenders are significant shareholders and insiders of the company.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260126:nNDL8btBRL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"gpt_icon":0},{"id":"2592117839","title":"Nuo Therapeutics Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592117839","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592117839?lang=en_us&edition=fundamental","pubTime":"2025-12-18 00:09","pubTimestamp":1765987795,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics Inc. held its 2025 Annual Meeting of Stockholders on December 16, 2025. At the meeting, stockholders elected David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer to the board of directors. Stockholders also ratified the appointment of MaloneBailey LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025. All proposals considered at the meeting were approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 17, 2025, and is solely respon","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDL5YByhZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"gpt_icon":0},{"id":"2591935833","title":"Nuo Therapeutics Initiated at Buy by Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2591935833","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591935833?lang=en_us&edition=fundamental","pubTime":"2025-12-16 23:30","pubTimestamp":1765899000,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/AURX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 10:30 ET (15:30 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","AURX","LENZ","BK4007"],"gpt_icon":0},{"id":"2588020644","title":"Nuo Therapeutics CEO/CFO David Emerson Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588020644","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588020644?lang=en_us&edition=fundamental","pubTime":"2025-12-04 07:13","pubTimestamp":1764803622,"startTime":"0","endTime":"0","summary":"David Emerson Jorden, CEO and CFO of Nuo Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 03, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251203:nNDL30Gnwb:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nuo Therapeutics CEO/CFO David Emerson Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":7,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AURX\",params:#limit:6,delay:false,,,undefined,":[]}}